David M Irlbeck

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. ncbi Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals
    David M Irlbeck
    GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    AIDS 22:1425-31. 2008
  2. ncbi Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism
    James F Demarest
    GlaxoSmithKline Virology, Research Triangle Park, North Carolina 27709, USA
    Antimicrob Agents Chemother 53:1116-23. 2009
  3. ncbi Virologic failure in therapy-naive subjects on aplaviroc plus lopinavir-ritonavir: detection of aplaviroc resistance requires clonal analysis of envelope
    Kathryn M Kitrinos
    GlaxoSmithKline Virology, Research Triangle Park, North Carolina 27709, USA
    Antimicrob Agents Chemother 53:1124-31. 2009
  4. ncbi Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1
    Mark R Underwood
    GlaxoSmithKline, Inc, Research Triangle Park, North Carolina 27709 3398, USA
    J Infect Dis 199:84-8. 2009

Collaborators

Detail Information

Publications4

  1. ncbi Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals
    David M Irlbeck
    GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    AIDS 22:1425-31. 2008
    ....
  2. ncbi Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism
    James F Demarest
    GlaxoSmithKline Virology, Research Triangle Park, North Carolina 27709, USA
    Antimicrob Agents Chemother 53:1116-23. 2009
    ..The acquisition of the M184V mutation is the primary characteristic of virologic failure in first-line therapy with aplaviroc plus lamivudine-zidovudine, regardless of the envelope tropism...
  3. ncbi Virologic failure in therapy-naive subjects on aplaviroc plus lopinavir-ritonavir: detection of aplaviroc resistance requires clonal analysis of envelope
    Kathryn M Kitrinos
    GlaxoSmithKline Virology, Research Triangle Park, North Carolina 27709, USA
    Antimicrob Agents Chemother 53:1124-31. 2009
    ..Virologic failure during a regimen of aplaviroc and lopinavir-ritonavir may be associated with aplaviroc resistance, only at the clonal level, and/or, infrequently, tropism changes...
  4. ncbi Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1
    Mark R Underwood
    GlaxoSmithKline, Inc, Research Triangle Park, North Carolina 27709 3398, USA
    J Infect Dis 199:84-8. 2009
    ..These findings underscore the limitations of stand-alone phenotypic susceptibility measures and emphasize the importance of complementary and/or more sensitive techniques...